Alzamend Neuro, Inc. (ALZN) Income Statement
ALZN FY2026 at a glance
Fiscal year ended April 30, 2026 · U.S. dollarsALZN revenue and net income
ALZN growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ALZN quarterly EPS vs estimates
Alzamend Neuro beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: December 8, 2026 (estimate $-0.23).
ALZN income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $50,740 | $50,740 | $23,066 | — | — | — | — | — | — |
| Gross profit | — | −$50,740 | −$50,740 | −$23,066 | — | — | — | — | — | — |
| Research & development | $3.6M | $1.4M | $6.5M | $7.4M | $5.2M | $1.3M | $1.1M | $3.7M | $323,403 | $275,047 |
| Sales, general & admin | $5.1M | $3.1M | $3.5M | $7.4M | $7.1M | $3.6M | $3.4M | $1.3M | $575,027 | $1.3M |
| Total operating expenses | $8.8M | $4.5M | $9.9M | $14.9M | $12.3M | $5.0M | $4.4M | $5.0M | $898,430 | $1.5M |
| Operating income | −$8.8M | −$4.5M | −$9.9M | −$14.9M | −$12.3M | −$5.0M | −$4.4M | −$5.0M | −$898,000 | −$1.5M |
| Interest income | $1,078 | $0 | — | — | $0 | $1,706 | $13,925 | $146,387 | — | — |
| Interest expense | $6,619 | $18,029 | $10,101 | $7,701 | $46,524 | $158,803 | $13,925 | $0 | $0 | $0 |
| Income before taxes | −$8.8M | −$4.5M | −$9.9M | −$14.9M | −$12.4M | −$5.0M | −$4.4M | −$4.9M | −$932,000 | −$1.6M |
| Income taxes | — | — | — | −$145,000 | $42,524 | $157,097 | −$13,925 | −$146,387 | −$898,000 | −$21,501 |
| Net income | −$8.8M | −$4.5M | −$9.9M | −$14.9M | −$12.4M | −$5.0M | −$4.4M | −$4.9M | −$932,000 | −$1.6M |
| EBITDA | −$8.7M | −$4.4M | −$9.9M | −$14.8M | −$12.3M | −$5.0M | −$4.4M | −$5.0M | $7,341 | −$21,501 |
| EPS (diluted) | −$2.90 | −$26.04 | −$87.19 | −$202.50 | −$94.57 | −$0.06 | −$0.07 | −$0.07 | −$0.05 | −$0.04 |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $76,110 | $0 | $0 |
| Cost of revenue | $27,685 | $27,685 | $27,685 | $27,685 | $27,685 | $12,685 | $12,685 | $12,685 | $12,685 | $12,685 | $12,685 | $12,685 |
| Gross profit | −$27,685 | −$27,685 | −$27,685 | −$27,685 | −$27,685 | −$12,685 | −$12,685 | −$12,685 | −$12,685 | −$12,685 | −$12,685 | −$12,685 |
| Research & development | $1.1M | $434,006 | $1.3M | $176,283 | $1.7M | $450,157 | $447,111 | $311,088 | $206,571 | $183,430 | $1.9M | $2.0M |
| Sales, general & admin | $1.9M | $2.6M | $919,025 | $821,826 | $959,334 | $688,779 | $590,304 | $1.0M | $755,834 | $666,635 | $763,858 | $904,939 |
| Total operating expenses | $3.0M | $2.8M | $2.2M | $998,109 | $2.7M | $1.1M | $1.0M | $1.4M | $962,405 | $850,064 | $2.7M | $2.9M |
| Operating income | −$3.0M | −$2.9M | −$2.2M | −$998,109 | −$2.7M | −$1.1M | −$1.0M | −$1.4M | −$962,405 | −$850,064 | −$2.7M | −$2.9M |
| Interest income | $399 | — | — | — | $0 | — | — | — | — | — | — | — |
| Interest expense | $2,005 | $13,088 | $1,337 | $2,649 | $2,483 | $509 | $2,019 | $3,495 | $12,006 | $1,465 | $2,488 | $4,311 |
| Income before taxes | −$3.0M | −$2.9M | −$2.2M | −$1.0M | −$2.7M | −$1.1M | −$1.0M | −$1.4M | −$974,411 | −$851,530 | −$2.7M | −$2.9M |
| Income taxes | — | — | — | — | — | — | — | — | — | −$2 | −$5 | — |
| Net income | −$3.0M | −$2.9M | −$2.2M | −$1.0M | −$2.7M | −$1.1M | −$1.0M | −$1.4M | −$974,411 | −$851,529 | −$2.7M | −$2.9M |
| EBITDA | −$3.0M | −$2.8M | −$2.2M | −$970,424 | −$2.7M | −$1.1M | −$1.0M | −$1.3M | −$949,720 | −$837,380 | −$2.6M | −$2.9M |
| EPS (diluted) | −$0.68 | −$0.74 | −$0.58 | −$0.30 | −$1.28 | −$9.48 | −$1.71 | −$3.60 | −$11.25 | −$13.35 | −$34.20 | −$39.60 |
| Gross margin | — | — | — | — | — | — | — | — | — | −16.7% | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | −1,116.9% | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | −1,118.8% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ALZN's financial statements (latest annual report filed July 22, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ALZN financial results
Alzamend Neuro reported no revenue in fiscal year 2026 (ended April 30, 2026). It had a net loss of $8.8 million. Diluted earnings per share came to −$2.90.
See the ALZN stock overview for the latest quote and news, or the ALZN chart for price history and technical indicators.
ALZN income statement FAQ
Does Alzamend Neuro have revenue?
Alzamend Neuro reported no revenue for fiscal year 2026, which ended on April 30, 2026.
Is Alzamend Neuro profitable?
No. Alzamend Neuro reported a net loss of $8.8 million in fiscal 2026.
How much does Alzamend Neuro spend on research and development?
Alzamend Neuro spent $3.6 million on research and development in fiscal 2026.
What are Alzamend Neuro's earnings per share?
Alzamend Neuro earned $-2.90 per diluted share in fiscal 2026, compared with $-26.04 a year earlier.
When will Alzamend Neuro report its next earnings?
Alzamend Neuro is expected to report results for the quarter ending October 31, 2026 on December 8, 2026.
When does Alzamend Neuro's fiscal year end?
Alzamend Neuro's fiscal year ends in April. The latest annual report covers the year ended April 30, 2026 and was filed on July 22, 2026.